Antibiotic treatment to reduce COPD flare-ups
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether giving a special antibiotic treatment to clear a common lung fungus (Pneumocystis jirovecii) can reduce how often COPD flare-ups happen. If you qualify, this might help you have fewer severe episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years old or older.
- You must have COPD that is confirmed by a breathing test showing airflow limitation.
- In the past year, you must have had at least one moderate or severe flare-up (worsening) of your COPD.
- You must be on a stable triple inhaler therapy (or double therapy if you cannot take steroids) for at least 1 month before starting.
- A sputum test must show you carry Pneumocystis jirovecii (a common fungus in the lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for people with COPD who still have frequent flare-ups despite using two maintenance inhalers. It aims to see if the study medicine can reduce these flare-ups.
This study tests an experimental medication for chronic obstructive pulmonary disease (COPD) in two parts: first in healthy volunteers, then in people with COPD. It aims to see if the drug is safe and how well it works.
This study tests an experimental drug called JKN2403 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve breathing compared to a placebo (a dummy pill).
This trial checks whether using fast test results (PCR from samples, a blood marker called procalcitonin, and sputum appearance) can safely reduce how long you need antibiotics during a severe COPD flare. It may help you receive fewer days of antibiotics while still controlling the infection risk.
This trial is testing a new way to choose antibiotics for people with COPD who get pneumonia and need intensive care. The goal is to find the best treatment using a personalized approach.
This study tests whether measuring two blood markers (MxA and CRP) can help doctors decide if antibiotics or antiviral drugs are needed for a COPD flare-up. It aims to reduce unnecessary antibiotic use while still treating infections effectively.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.